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Decreased postural control in 
adult survivors of childhood cancer 
treated with chemotherapy
Einar-Jón Einarsson1,2, Mitesh Patel3, Hannes Petersen2,4, Thomas Wiebe5,  
Per-Anders Fransson1, Måns Magnusson1,6 & Christian Moëll5
The objective of cancer treatment is to secure survival. However, as chemotherapeutic agents can affect 
the central and peripheral nervous systems, patients must undergo a process of central compensation. 
We explored the effectiveness of this compensation process by measuring postural behaviour in adult 
survivors of childhood cancer treated with chemotherapy (CTS). We recruited sixteen adults treated 
with chemotherapy in childhood for malignant solid (non-CNS) tumours and 25 healthy age-matched 
controls. Subjects performed posturography with eyes open and closed during quiet and perturbed 
standing. Repeated balance perturbations through calf vibrations were used to study postural 
adaptation. Subjects were stratified into two groups (treatment before or from 12 years of age)  
to determine age at treatment effects. Both quiet (p = 0.040) and perturbed standing (p ≤ 0.009) were 
significantly poorer in CTS compared to controls, particularly with eyes open and among those treated 
younger. Moreover, CTS had reduced levels of adaptation compared to controls, both with eyes closed 
and open. Hence, adults treated with chemotherapy for childhood cancer may suffer late effects of 
poorer postural control manifested as reduced contribution of vision and as reduced adaptation skills. 
These findings advocate development of chemotherapeutic agents that cause fewer long-term side 
effects when used for treating children.
The maintenance of postural control in humans requires continuous integration of sensory inputs from visual, 
vestibular and somatosensory receptors (proprioceptors and mechano-receptors) by the Central Nervous 
System (CNS) to assess position and motion of the body1. The fundamental mechanisms behind postural control 
(e.g. sensorimotor development and functional ability) are formed and modified between childhood and adoles-
cence through physical activity2. The developmental process of postural control involves several phases such as 
building repertoires of different postural strategies and learning how to apply these strategies to different environ-
ments through exploration3,4. Another process is learning to anticipate events and selecting the most appropriate 
strategy5. Children with conditions that affect these processes may never master complex motor repertoires.
The treatment of childhood cancer often requires a concoction of different chemotherapeutic agents of vary-
ing quantities. However, chemotherapeutic agents are destructive in nature and could lead to poor postural con-
trol and sensorimotor development, either through direct action (i.e. by impairing sensory or motor functions) or 
indirectly (i.e. side-effects such as fatigue or nausea which may render the child bedridden for extended periods 
of time). For example, motor problems including postural instability have been found in children 2–7 years after 
completion of chemotherapy where vincristine has been part of the treatment6–8. Vincristine can cause decreased 
peripheral muscle strength6, disrupt control of ankle dorsiflexion9,10 and cause polyneuropathy which may lead 
to lower leg sensory loss11. Reports suggest that the late effects from vincristine are influenced by the child’s age 
at treatment, with early infants most heavily affected12. Moreover, vincristine and methotrexate can cause neu-
rotoxicity13,14 but these effects may first appear several years after treatment15. Another chemotherapeutic agent 
known to have detrimental effects on children is cisplatin, which is both neurotoxic16 and ototoxic and may 
damage the vestibular and auditory systems17–19. Subsequently, ototoxicity can potentially result in dizziness and 
disequilibrium20.
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Significant work has been carried out to study the long-term effects of chemotherapy in children15,21 but no 
previous studies have considered the effects on adaptive postural control which is fundamental to meet the pres-
sures of physical environments. As chemotherapeutic agents administered in childhood could damage the sen-
sory and motor systems, an improper development of these systems in survivors of childhood cancer may lead to 
long-term postural instability. Such deficits are more likely to be revealed when stability is challenged22. Vibration 
of skeletal muscles or tendons is a common method used to controllably perturb balance and assess an individ-
ual’s ability to maintain a stable stance23. When repeated, the brain generates sensorimotor predictions about the 
likely outcome of the event and accordingly adapts our motor plans24. This is an error based motor learning pro-
cess that quickly allows modification of motor strategies to maintain postural control4. Sensorimotor adaptation 
is an essential feature of postural control since it decreases fall risk25 - normal individuals should quickly be able 
to learn the characteristics of a balance challenge and set their balance system to minimise these effects4.
The aim of this study was to investigate postural control and adaptation in adult survivors of childhood cancer 
treated with chemotherapy. To study the long-term effects of chemotherapy on postural control, the subjects were 
assessed on average 15 years after end of treatment. The subjects recruited had been treated for malignant solid 
tumour types commonly found in children and had been treated with common types of chemotherapy medica-
tion. Strict selection criteria for the malignancy were used to avoid confounding peripheral or central nervous 
system involvement. Another aim was to determine if the age at the time of chemotherapy treatment influences 
postural stability. This investigation is part of a set of studies in which adult populations, treated for cancer with 
chemotherapy at young age, have been screened for late subjective and neurological symptoms18,19,26.
Results
Quiet stance stability. There was no significant difference between CTS and healthy controls for quiet 
stance postural stability (ANOVA, Table 1). Vision significantly increased stability in both subject groups, i.e., 
reduced used total (p < 0.001), low frequency (p = 0.034) and high frequency energy (p < 0.001). There was no 
evidence of interaction between having chemotherapy and vision.
Sub-group analyses showed that CTS_Young had poorer stability compared to controls and CTS_Old. CTS_
Young used more total energy in quiet stance than controls (p = 0.040). Moreover, CTS_Young used more high 
frequency energy than CTS_Old (p = 0.049). Post-hoc analysis confirmed that CTS_Young had used more total 
and high frequency energy with eyes open compared to controls (p ≤ 0.023) and CTS_Old (p ≤ 0.016) (Fig. 1).
Perturbed stance stability. During balance perturbations, CTS had significantly poorer stability compared 
to controls as reflected by higher use of total (p = 0.012), low frequency (p = 0.024) and high frequency energy 
(p = 0.019) (ANOVA, Table 2). In the ANOVA, vision significantly increased stability in CTS and controls i.e., 
used total (p < 0.001), low (p = 0.049) and high frequency energy (p < 0.001) were lower with eyes open com-
pared to closed. CTS and controls showed significant adaptation (ANOVA p < 0.001 for all frequency spectra) 
i.e., a reduction of used total, low frequency and high frequency energy to address repeated perturbations 
across Periods (i.e., Periods 1–4). In the investigation of interactions between main factors, CTS used more high 
Quiet stance 
stability Chemotherapy* Vision
Chemotherapy 
x Vision
CTS vs healthy controls
 Total 0.128 [2.4] <0.001 [17.6] 0.832 [0.0]
 < 0.1 Hz 0.243 [1.4] 0.034 [4.8] 0.712 [0.1]
 > 0.1 Hz 0.278 [1.2] <0.001 [30.8] 0.396 [0.7]
CTS_Young vs healthy controls
 Total 0.040 [4.6] 0.003 [10.2] 0.571 [0.3]
 < 0.1 Hz 0.139 [2.3] 0.113 [2.6] 0.519 [0.4]
 > 0.1 Hz 0.063 [3.7] <0.001 [18.4] 0.837 [0.0]
CTS_Old vs healthy controls
 Total 0.965 [0.0] 0.002 [11.1] 0.716 [0.1]
 < 0.1 Hz 0.886 [0.0] 0.073 [3.5] 0.879 [0.0]
 > 0.1 Hz 0.571 [0.3] <0.001 [27.8] 0.067 [3.6]
CTS_Young vs CTS_Old
 Total 0.127 [2.6] 0.012 [8.3] 0.426 [0.7]
 < 0.1 Hz 0.385 [0.8] 0.227 [1.6] 0.563 [0.4]
 > 0.1 Hz 0.049 [4.6] 0.001 [15.6] 0.135 [2.5]
Table 1.  Effects of chemotherapy and vision on the stability during quiet stance. Repeated measures GLM 
ANOVA analysis of how the quiet stance stability were affected by main factors “Chemotherapy” and “Vision” 
alone and by the main factor interaction denoted as “Chemotherapy x Vision”. The notation “< 0.001” means 
that the p-value is smaller than 0.001. F-values are presented in the squared parenthesis. *In the CTS_Young 
vs CTS_Old GLM Anova evaluation the main factor “chemotherapy” represents the effect of receiving 
chemotherapy below 12 years of age (CTS_Young) vs from 12 years of age and older (CTS_Old).
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frequency energy over time (i.e., in Periods 3 and 4) than controls (p = 0.017) and especially with eyes closed 
(p = 0.022), see also Fig. 1.
When studying age at treatment effect, CTS_Young had poorer stability compared to controls in all spectral 
categories (p ≤ 0.009). Main factor interactions revealed that energy used over time increased during posturog-
raphy in CTS_Young compared to controls (p = 0.042), that the pattern of energy used over time were systemat-
ically different between eyes closed and open (p = 0.016) and that the CTS_Young used more energy over time 
compared to controls with eyes closed (p = 0.008). When comparing the CTS_Old and controls the stability was 
similar. However, when comparing CTS_Young with CTS_Old, CTS_Young used significantly more high fre-
quency energy especially in the last periods of tests with eyes closed (p = 0.045).
Post-hoc analysis confirmed poorer stability during balance perturbations in CTS compared to controls for 
Period 3 in total and low frequency energy with eyes closed (p ≤ 0.040); and with eyes open during Period 1 in 
total and high frequency energy (p ≤ 0.007), Period 3 in total and low frequency energy (p ≤ 0.046) and Period 4 
in total and high frequency energy (p ≤ 0.049) (Fig. 1).
When studying age at treatment effect, CTS_Young had poorer stability with eyes closed than controls and 
the differences were accentuated over time especially as increased total and high frequency energy used during 
vibration Periods 3 and 4 (p ≤ 0.038). However, CTS_Young also had poorer stability with eyes open compared to 
Figure 1. Total, low frequency and high frequency spectral energy used towards the supporting surface 
during the 5 sequential time periods during posturography. The figure present normalised; (a) total, (b) low 
frequency and (c) high frequency torque variance values, representing kinds of spectral energy, used during 
posturography while standing with Eyes Closed and Eyes Open (mean and SEM). Values and statistical findings 
to the level of trends (p < 0.1) are presented for healthy controls (n = 25), for all chemotherapy treated subjects 
CTS (n = 16), and for the subgroups CTS treated with chemotherapy below 12 years of age CTS_Young (n = 10) 
and CTS treated from 12 years of age and older CTS_Old (n = 6).
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controls for total energy in Periods 1-4 (p ≤ 0.019) and in low and high frequency energy during Periods 1, 3 and 
4 (p ≤ 0.049). In post-hoc tests, there was no significant difference between CTS_Old and controls.
Adaptation capacity. When investigating the ability to adapt to the repeated balance perturbations between 
Period 1 and Period 4 (i.e., the maximum level of learning), controls showed significant adaptation in all fre-
quency spectra with eyes closed (p < 0.001) and eyes open (p ≤ 0.002) (Table 3). CTS also showed significant 
adaptation in all frequency spectra with eyes open (p ≤ 0.005) but only in the total and low frequency spectra with 
eyes closed (p ≤ 0.006), not in the high frequency spectra. The level of adaptation was poorer in CTS compared 
to controls.
A further analysis of the effect of age at treatment revealed that CTS_Young had no significant adaptation to 
balance perturbations with eyes closed and a significant adaptation limited to total and low frequency spectra 
with eyes open (p ≤ 0.004). CTS_Old had a significant adaptation limited to total and low frequencies with eyes 
closed (p ≤ 0.031), and only in the high frequency spectra with eyes open (p = 0.031).
Discussion
The primary objective with cancer treatment is to secure the survival of the patient. This primary objective has 
increasingly been achieved in the last few decades by the introduction of new, more effective treatments, which 
have substantially improved survival rates especially when treating children and adolescents. However, this suc-
cess has highlighted the importance of monitoring long-term effects from the cancer and from the treatments 
used in order to improve the overall quality of life in cancer survivors, particularly for neurodevelopment21. 
Considering the long time span during which side-effects from chemotherapy may develop, a specific objective of 
this study was to investigate for impairments in postural control and sensorimotor adaptation in adult survivors 
of childhood cancer. For example, neuropathy, a known neurotoxic side effect from vincristine and methotrex-
ate13,14, may appear first several years after the end of treatment15. Moreover, ototoxic drugs induce a gradual loss 
of sensory cells and primary vestibular neurons17,20, which may develop into a significant functional lesion many 
years after the end of treatment. This study revealed that adults treated with chemotherapy in childhood have 
poorer postural control compared to controls, on average 16 years after the end of treatment, which is consistent 
with other reports6,27. Moreover, the stability issues were manifested as similarly increased use of energy in all 
spectral categories, i.e., both as more smooth corrective changes of posture (i.e. < 0.1 Hz) and more fast reflexive 
corrective movements to maintain balance (i.e. > 0.1 Hz), suggesting that the deficits in CTS affects several sen-
sorimotor systems28–31. Another new finding in this study is that subjects treated at younger age are more likely to 
experience poor postural control as an adult.
Importantly, this study suggests that the developmental state of being a child or adolescent at the time of treat-
ment might be a critical factor influencing the severity of any related impairment into adulthood. The postural 
control deficits were found to be significantly more severe among those treated at younger age, affecting both the 
ability to utilise vision and adaptation to enhance postural control during balance perturbations. It is possible that 
the immaturity of the peripheral and central nervous systems in children made these systems more susceptible 
to physical and functional changes and irreversible damage from chemotherapeutic agents20. Another possibility 
Perturbation 
stability Chemo Vision Period
Chemo x 
Vision
Chemo x 
Period
Vision x 
Period
Chemo x 
Vision x Period
CTS vs healthy controls
 Total 0.012 [7.0] <0.001 [66.2] <0.001 [125.9] 0.652 [0.2] 0.095 [2.9] 0.251 [1.4] 0.452 [0.6]
 < 0.1 Hz 0.024 [5.5] 0.049 [4.1] <0.001 [113.6] 0.865 [0.0] 0.112 [2.6] 0.334 [1.0] 0.570 [0.3]
 > 0.1 Hz 0.019 [6.0] <0.001 [129.3] <0.001 [55.6] 0.421 [0.7] 0.017 [6.3] 0.076 [3.3] 0.022 [5.7]
CTS_Young vs healthy controls
 Total 0.003 [9.9] <0.001 [43.9] <0.001 [85.2] 0.483 [0.5] 0.124 [2.5] 0.098 [2.9] 0.171 [2.0]
 < 0.1 Hz 0.006 [8.8] 0.335 [1.0] <0.001 [76.8] 0.535 [0.4] 0.227 [1.5] 0.172 [2.0] 0.360 [0.9]
 > 0.1 Hz 0.009 [7.6] <0.001 [96.4] <0.001 [42.0] 0.610 [0.3] 0.042 [4.5] 0.016 [6.5] 0.008 [7.9]
CTS_Old vs healthy controls
 Total 0.500 [0.5] <0.001 [32.3] <0.001 [78.2] 0.911 [0.0] 0.297 [1.1] 0.805 [0.1] 0.610 [0.3]
 < 0.1 Hz 0.597 [0.3] 0.027 [5.5] <0.001 [69.5] 0.278 [1.2] 0.162 [2.1] 0.691 [0.2] 0.555 [0.4]
 > 0.1 Hz 0.430 [0.6] <0.001 [49.8] <0.001 [34.2] 0.465 [0.5] 0.071 [3.5] 0.262 [1.3] 0.516 [0.4]
CTS_Young vs CTS_Old
 Total 0.103 [3.1] <0.001 [34.6] <0.001 [46.3] 0.469 [0.6] 0.579 [0.3] 0.301 [1.2] 0.144 [2.4]
 < 0.1 Hz 0.181 [2.0] 0.045 [4.8] <0.001 [44.6] 0.082 [3.5] 0.497 [0.5] 0.524 [0.4] 0.226 [1.6]
 > 0.1 Hz 0.177 [2.0] <0.001 [64.6] <0.001 [30.8] 0.679 [0.2] 0.708 [0.1] 0.057 [4.3] 0.045 [4.8]
Table 2.  Effects of chemotherapy, vision and vibration period on the stability during balance 
perturbations. Repeated measures GLM ANOVA analysis of how the perturbed stance stability were affected 
by main factors “Chemotherapy” (denoted Chemo in the table) “Vision” and “Period” alone and by their main 
factor interactions *In the CTS_Young vs CTS_Old GLM Anova evaluation the main factor “chemotherapy” 
represents the effect of receiving chemotherapy below 12 years of age (CTS_Young) vs from 12 years of age and 
older (CTS_Old).
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is that if severe peripheral or central impairments are received before the developmental stages of sensory and 
motor systems are complete, these systems may never fully recover through central compensation. A limitation 
of this study is that tests were not carried out repeatedly from the end of treatment to map systematic changes 
in performance over time. However, our findings are a strong indication that longitudinal assessments should 
be performed regularly on subjects treated in childhood with chemotherapy for at least 20 years after the end of 
treatments.
The visual system usually plays an important role in the maintenance of postural stability, especially when 
information from other sensory receptors is unreliable. The present study showed that during perturbations, 
visual information (eyes open) improved stability in CTS compared with absent visual information (eyes closed). 
However, the level of improvement of stability when utilising vision was lower compared to controls. Interestingly, 
problems associated with the visual system have been found in chemotherapy treated subjects in previous psy-
chophysical and questionnaire investigations26, where difficulties with visual tasks were identified by CTS them-
selves26. Thus, the similarities in objective and subjective measurements are compelling regarding this matter. 
Experimental alterations in visual performance (i.e. clarity and acuity) are known to decrease postural stability 
in eyes open tests32,33, and a number of vestibular disorders can impair oculomotor control, causing oscillopsia34. 
Hence, reduced or altered vestibular and/or visual performance could partly account for the poorer stability in 
CTS. It is possible that the CNS is either not able to fully utilise the visual information properly to enhance pos-
tural control or that the spatial and/or temporal information provided by the visual system is less reliable in CTS.
Subjects treated as children with chemotherapy had impaired sensorimotor adaptation of postural control 
evidenced by poor motor learning to repeated perturbations, both when standing with eyes closed and open. 
Specifically, for CTS_Young, adaptation without vision proved challenging. The explicitly poorer than normal 
performance during the last two 50-second periods of the posturography tests suggest that a contributing factor 
might be that repeated perturbations for over 2 minutes became increasingly physically and/or mentally fatigu-
ing. Moreover, using positron emission tomography, Silverman et al.35 found alterations in resting metabolism 
and cerebral blood flow in the basal ganglia, inferior frontal gyrus and cerebellum during memory activation in 
women who had received chemotherapy 5–10 years earlier. These CNS areas are all associated with sensorimotor 
adaptation. In addition, several studies report hippocampal atrophy as a post-effect from chemotherapy36–38. 
Decreased adaptive capacity might also be caused by decreased peripheral sensory information, which may hin-
der the CNS from getting the information needed to allow an effective adaptive process39. Known side-effects 
from chemotherapy agents include polyneuropathy, which may cause decreased somatosensory sensation, and 
ototoxity which may produce vestibular lesions11,16,17. Thus, if chemotherapy results in impairment of adaptation, 
it may limit the efficacy of rehabilitation and training programs40. In a subgroup of our material, signs of ototoxity 
were explored by comparing hearing levels before chemotherapy and at the time of posturography, on average 
about 16 years later. These assessments revealed substantial hearing losses in 4 out of 10 investigated subjects. 
However, when statistically evaluated, no finding or trend suggested more impaired postural control among those 
who had suffered hearing loss.
Possible causes for long-term impairments after childhood cancer may not only include the chemotherapy 
treatment received but may also include lesions produced by the cancer itself or be a consequence of the interven-
tion treatment (surgical removal and radiation). Strict criteria for the malignancy were therefore applied in this 
study to avoid confounding peripheral or central nervous system impairment from the cancer itself, radiation or 
surgery treatments. Another consideration is that the cancer and treatments might make the child fatigued or 
Stability changes*
Vibration period 1 vs period 4
Eyes Closed Eyes Open
Healthy controls
 Total <0.001 [−48] <0.001 [−59]
 < 0.1 Hz <0.001 [−64] <0.001 [−73]
 > 0.1 Hz <0.001 [−36] 0.002 [−29]
CTS
 Total 0.005 [−30] 0.001 [−48]
 < 0.1 Hz 0.006 [−40] 0.002 [−55]
 > 0.1 Hz 0.058 [−22] 0.005 [−40]
CTS_Young
 Total 0.160 [−21] 0.002 [−51]
 < 0.1 Hz 0.232 [−29] 0.004 [−60]
 > 0.1 Hz 0.432 [−15] 0.084 [−41]
CTS_Old
 Total 0.031 [−50] 0.156 [−37]
 < 0.1 Hz 0.031 [−65] 0.438 [−36]
 > 0.1 Hz 0.063 [−38] 0.031 [−37]
Table 3.  Stability changes between vibration period 1 and vibration period 4 when standing with Eyes 
Closed and Eyes Open. *Stability changes as reflected by increased/decreased use of energy in percent are 
presented within the squared parenthesis.
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nauseated, which may render the child bedridden and inactive for extended periods of time during a part of their 
life where many of the physical and sensory systems are still in a process of development. This may postpone the 
natural development of motor skills2.
Nevertheless, due to severity and range of side-effects experienced many years after chemotherapy treatment 
and the growing awareness of relationships between chemotherapeutic agents and a multitude of long-term 
adverse effects16, the most likely cause for long-term impairments after childhood cancer is the chemotherapy 
treatment received. Chemotherapy is generally not very specific, and it puts normal tissues and organs at risk. 
Although the brain is given some protection from systemic treatments by the blood-brain barrier, it is increas-
ingly recognized that many chemotherapeutic agents affect central brain function through direct and/or indirect 
mechanisms41. Moreover, the long-term consequences of most chemotherapeutic agents on the CNS have rarely 
been considered42. However, Dietrich and colleagues have recently showed that clinically relevant concentrations 
of 1,3-bis(2-chlorthyl)-1-nitrosoura (BCNU) and cisplatin, are even more toxic to CNS progenitor cells and oli-
godendrocytes than they are to cancer cell lines43. Furthermore, therapeutic levels of 5-fluorouracil (5-FU) is 
associated with progressive delayed damage to myelin44.
The objective of this study was not to determine the long-term effect of specific chemotherapy drugs but to 
investigate if subjects in general with this medical history suffer from postural instability and reduced adaptation 
even 15 years after treatment. However, this study illustrates the complexity of determine the effects of individual 
chemotherapy agents. As shown in Table 4, the treatment of childhood cancer often requires a concoction of 
different chemotherapeutic agents applied in varying quantities and over different durations. Hence, large-scale, 
long-term studies are likely necessary to identify drug-associated side-effects, e.g., whether certain drugs are more 
toxic than others and under what circumstances impairments from chemotherapy treatment in children occur. 
This information would though be markedly useful in order to detect, prevent and treat the impairments from 
chemotherapy treatment.
Previous reports have largely implicated vincristine as the causative agent for impaired postural control 
reported in chemotherapy treated subjects several years after the end of treatment6,11,45, though the effect of other 
drugs such as methotrexate13,14 and cisplatin17 should not be ruled out. Furthermore, a strict causal relationship 
between cumulative vincristine dose and motor performance has not yet been proved, although low doses of 
vincristine have been found to decrease motor control6. Moreover, many chemotherapeutic agents including 
vincristine, cisplatin and carboplatin affect the eye periphery and subsequent sensory information, which could 
result in grey-matter atrophy in the occipital lobe16. However, it is particularly interesting that vincristine induces 
neuropathy to cranial nerves, especially of the ocular motor nerves46,47. Any structural brain changes in children 
could interfere with normal development resulting in abnormal function of the affected area48.
It is also important to consider to what extent chemotherapy treated subjects suffer from various subjective 
and neurological symptoms causing reduced quality of life and where some symptoms may be associated with 
impoverished postural control. We have previously investigated oculomotor and neurological status, and subjec-
tive symptoms in a somewhat larger study population in which the subjects participating in this study also took 
part26. We noted a similar trend as in this study that subjects treated before 12 years of age experienced greater 
impairments from the chemotherapy treatments received. The study also found among the test subjects marked 
Subject Diagnosis Gender
Age at treatment 
(years)
Age when assessed 
(years)
Brock’s hearing 
loss graders **
Chemotherapy treatment 
agents*
1 Sacrococcygeal teratoma Female 0.1 23.4 0 Ble, Cis, Eto
2 Hepatoblastoma Female 2.5 15.9 — Adr, Cis
3 Embryonal teratoma Female 2.5 17.7 2 Ble, Cis, Eto
4 Ewing sarcoma Male 2.9 16.4 — Act, Adr, Eto, Ifo, Vin
5 Ewing sarcoma Female 8.6 30.0 — Act, Adr, Ble, Cyc, Met, Vin
6 Neuroblastoma Male 8.9 21.4 3 Car, Cis, Cyc, Eto, Mel, Vin
7 Immature teratoma Female 9.1 18.5 0 Ble, Cis, Eto
8 Ewing sarcoma Male 9.6 30.3 — Act, Adr, Ble, Cyc, Met, Vin
9 Immature teratoma Female 10.3 35.8 — Act, Adr, Cyc, Vin
10 Ewing sarcoma Male 10.7 33.1 3 Act, Adr, Ble, Cis, Cyc, Met, Vin
11 Osteosarcoma Female 14.3 33.9 1 Act, Adr, Ble, Cis, Cyc, Met
12 Ewing sarcoma Male 15.5 35.4 — Act, Adr, Ble, Cyc, Met, Vin
13 Ewing sarcoma Male 15.7 24.0 0 Adr, Cis, Ifo, Vin
14 Immature teratoma Male 16.5 27.8 0 Ble, Cis, Eto
15 Ewing sarcoma Male 16.8 23.7 0 Act, Adr, Cis, Cyc, Eto, Ifo, Vin
16 Osteosarcoma Male 16.9 30.9 0 Adr, Cis, Met
Table 4.  Subject characteristics, diagnosis and chemotherapy details. *Act: Actinomycin-D; Adr: 
Adriamycin; Ble: Bleomycin; Car: Carboplatin; Cis: Cisplatin; Cyc: Cyclophosphamide; Eto: Etoposide; Ifo: 
Ifosfamide; Mel: Melphalan; Met: Methotrexate; Vin: Vincristine. **Brock’s hearing loss grades: 0: < 40 dB at all 
frequencies. 1: ≥ 40 dB at 8 kHz only, and < 40 dB at all other frequencies. 2: ≥ 40 dB at 4 kHz and above, and  
< 40 dB at all other frequencies. 3: ≥ 40 dB at 2 kHz and above, and < 40 dB at all other frequencies. 4: ≥ 40 dB at 
1 kHz and above, and < 40 dB at all other frequencies.
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oculomotor control deficits and the subjects reported in a questionnaire frequent issues with visual disturbances, 
dizziness, light-headedness and perceptual unsteadiness. Taken together, the current findings and our previ-
ous findings suggest that several basic neurological functions and everyday actions are often impaired in adults 
treated with chemotherapy, specifically in adults treated with chemotherapy before 12 years of age.
Due to strict inclusion criteria subgroup numbers are small, which might affect the reliability of the subgroup 
statistical analyses. Moreover, there were clear gender, height and weight differences between subgroups CTS_
Young and CTS_Old. However, the lower weight and height found for CTS_Young are usually associated with 
better postural control, thus, the age at treatment related findings are not related to differences in anthropomet-
rics. Furthermore, the different ability to use vision to enhance stability is difficult to explain by anthropometrical 
differences between CTS_Young and CTS_Old.
Because of the strict inclusion criteria applied, the subject population investigated were stringently defined 
in terms of cancer type category (i.e., malignant solid tumours). Moreover, the inclusion criteria were carefully 
selected to ensure that the chemotherapy treatment received would be the only likely source for any late effects 
observed. However, the strict criteria applied made us in the end include only 16 subjects out of approximately 
750 patients in the total cohort investigated. Hence, since this study has validated the concept and determined a 
marked practical clinical relevance in a very strictly controlled material, a natural development of the research 
would be to perform prospective investigations carried out on larger and more homogenous populations, e.g., 
where all subjects had suffered from the same type of cancer (e.g., leukaemia in childhood) and where the treat-
ment procedures were more standardised. Moreover, future large cohort studies may also approach the complex 
but vital issues of childhood cancer treatments such as determining potential influences of cancer types, cancer 
locations, chemotherapy agents received, medication administration procedures and the sizes of accumulated 
medication dosages.
To conclude, neurotoxic signs and symptoms tend to decrease over time as a result of central adaptation6,49. 
However, we found poor postural control and adaptation on average 16 years after the end of treatment in CTS 
subjects, suggesting poor ability in this patient population to recover from chemotherapy treatment side effects. 
These findings emphasize the necessity to follow up, also long-term into adulthood, cancer patients treated in 
childhood with chemotherapy and to introduce early in the cancer treatment recovery programs also balance 
rehabilitation regimes. Moreover, the findings advocate development of chemotherapy agents that cause fewer 
and less harmful long-term side effects when used for treating children.
Methods
Experiments were performed in accordance with the Helsinki declaration and approved by the Scientific Ethical 
Committee at Lund University, Sweden (number LU964-03) and by the Data Protection Authority (number 
LU-P6103), Sweden. A non obstat statement was obtained from the Scientific Ethical Committee, that no addi-
tional ethical approval was required to perform the investigations as part of clinical follow-up of the patient pop-
ulation. All participants or their guardians, provided written informed consent before the testing commenced.
Subjects. Forty-one subjects, 16 chemotherapy treated subjects (CTS) and 25 healthy controls participated 
in the study. The CTS were recruited from all adults who survived childhood cancer in the county of Skåne, 
Sweden, between 1980 and 2000. Sixteen of approximately 750 adult survivors from the period, fulfilled the strict 
inclusion criteria: cancer diagnosed before the age of 18; treated for a malignant solid tumour not affecting CNS 
with chemotherapy agents and the treatment completed > 5 years before this study. Exclusion criteria from the 
study were if the subjects had received cranial radiotherapy or surgery which might have affected the CNS or had 
surgery affecting the legs or pelvis. Subjects who fulfilled all criteria were contacted by a clinical administrator and 
offered to participate in the study, which they all did. The investigations were performed without any selection 
bias.
The 16 CTS (7 females; mean age 26.1 years (SD 6.9); mean height 1.73 meters (SD 0.10); mean mass 71.2 kilo-
grams (SD 18.6)) were on average 10.1 years (SD 5.7) old when submitted to chemotherapy treatment and the 
subjects had on average completed the chemotherapy treatment 16.1 years (SD 5.8) before participating in this 
study. Additional treatment details are presented in Table 4. Ten of the sixteen subjects in this study underwent 
clinical hearing assessment before receiving chemotherapy, and thus, the changes in hearing level could be deter-
mined in these subjects at the time of posturography testing, see Table 4. When rating the hearing loss with 
Brock’s hearing loss grades, four of ten subjects had suffered a substantial hearing impairment during and after 
the chemotherapy treatment whereas the other six subjects had preserved normal hearing.
To determine whether the developmental state at treatment influenced postural control and sensorimotor 
adaptation, the CTS group was also divided into two age subgroups. One subgroup (CTS_Young), included all 
CTS that received treatment before 12 years of age (n = 10; 6 females; mean age 24.2 years (SD 7.4); mean height 
1.70 meters (SD 0.09); mean mass 67.3 kilograms (SD 22.3)) with mean age at treatment of 6.5 years (SD 4.0). 
The other subgroup (CTS_Old), included all CTS that received treatment from 12 years of age and older (n = 6 
subjects; 1 female; mean age 29.3 years (SD 5.0); mean height 1.80 meters (SD 0.12); mean mass 77.8 kilograms 
(SD 11.2)) with mean age at treatment of 16.0 years (SD 1.0). Statistical analyses showed no difference between 
subgroups for quantity and type of chemotherapy drugs received.
The age and gender-matched control group consisted of 25 healthy participants (13 women, mean age 25.1 
years (SD 4.6); mean height 1.75 meters (SD 0.09); mean mass 68.8 kilograms (SD 13.3)). All subjects included in 
the study, both controls and CTS, had normal or corrected to normal visual acuity using glasses or contact lenses.
Posturography assessment. A custom built force platform recorded torques and sheer forces with six 
degrees of freedom using force transducers with an accuracy of 0.5 N. A customised computer program controlled 
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the vibratory stimulation and sampled the force platform data at 50 Hz. The vibrators had vibration amplitude of 
1.0 mm and frequency of 85 Hz, were 6 cm long and 1 cm in diameter and strapped over the calf muscles.
Each participant stood barefoot on the force platform in an upright but relaxed posture with arms folded 
across the chest, heels 3 cm apart and feet positioned at an angle of 30° along guidelines on the platform, see 
Fig. 2. Participants were instructed to focus on a target 1.5 m in front of them at eye level or keep their eyes closed 
depending on the test condition. The participants listened to music through headphones to reduce possible move-
ment references from external noise sources and to avoid extraneous sound distractions. To ensure no prediction 
of the balance perturbation, all participants were naive to the stimulus and were not informed about the effect calf 
vibration would have on their balance.
Two tests were performed in a randomised order, using a Latin Square design, by all subjects:
(1) Vibration of the calf muscles with eyes closed (EC) and
(2) Vibration of the calf muscles with eyes open (EO).
Before vibration commenced, a 30 second control period of quiet stance was recorded. The vibratory stimula-
tions were applied according to a pseudorandom binary sequence (PRBS) schedule22 during a period of 200 sec-
onds making each trial 230 seconds long. The PRBS schedule defined the periodicity of stimulation pulses, where 
each pulse and each interval between pulses had random time duration from 0.8 seconds up to 6.4 seconds, which 
yielded an FFT-validated effective bandwidth of the test stimulus in the region of 0.1–2.5 Hz. The PRBS sequence 
was selected because this randomised stimulation sequence is difficult to predict and therefore lessens the like-
lihood of pre-emptive responses. The same PRBS schedule was used across all subjects and for all tests. A five 
minute rest period was given to the subjects between tests.
Analysis. Since calf vibration induces body movement mainly in the anteroposterior direction24, only the 
responses in the anteroposterior direction are considered here. Postural stability was measured as the variance 
of anteroposterior torque values. The torque produced at various sites of the body is the effective means used 
for controlling the orientation and stability of a standing organism50. Also, torque variance values correspond 
directly to the energy used towards the support surface to maintain stability51, which in turn corresponds to the 
efficiency of standing50. For a detailed explanation on torque and its relationship to standing postural control, see 
Johansson et al.51.
The force platform recordings were spectrally divided into total torque variance (total energy), torque below 
0.1 Hz (< 0.1 Hz; low frequency energy); and torque above 0.1 Hz (> 0.1 Hz; high frequency energy) using a 
fifth-order digital Finite duration Impulse Response (FIR) filter, with filter components selected to avoid aliasing. 
These separations were used to distinguish between smooth corrective changes of posture (i.e. < 0.1 Hz) and 
fast corrective movements to maintain balance (i.e. > 0.1 Hz)28. Clinically, increased fast corrective movements 
(> 0.1 Hz) are commonly associated with decreased visual information28 and by factors influencing motor con-
trol such as being over-weight or fatigued29, whereas the low frequency movements (< 0.1 Hz) are commonly 
increased by poor surface conditions like standing on foam30,31. Torque variance values were normalised to 
account for anthropometric differences between the subjects, using the subject’s squared height and squared 
weight, as height and weight are key factors influencing the body sway recorded by a force platform4,51. The 
squared nature of the variance algorithm made it necessary to use normalisation with squared parameters to 
achieve unit agreement.
Mean values for all parameters were obtained for five periods for each trial condition: the quiet stance 
period (0–30 s), and from four 50 s periods (Period 1: 30–80 s; Period 2: 80–130 s; Period 3: 130–180 s; Period 4: 
180–230 s) during the vibration. Each 50 s period contains a similar amount of long and short vibration pulses 
Figure 2. Schematic illustration of the posturography setup. The posturography software produces (1) a 
pseudorandom binary sequence (PRBS), which is (2) converted to vibration pulses. Vibration pulses applied 
towards (3) the calf muscles cause balance perturbations. The energy used (4) towards the support surface, 
reflecting the effort to maintain stability, is recorded by a force platform and quantified by the posturography 
software (5).
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validated by Fast-Fourier Transform (FFT)-analysis of spectral contents in the stimulation. Hence, the selected 
periods and perturbation sequence allowed analysis of whether the stability changed over time and possibly 
caused an adaptation to the unpredictable balance perturbations.
Statistical analysis. The torque variance values during quiet (unperturbed) stance and during balance per-
turbations were analysed using repeated measures GLM ANOVA on log-transformed values. The main factors 
and factor interactions analysed were: ‘Chemotherapy’ (CTS (n = 16), CTS_Young (n = 10), CTS_Old (n = 6) 
vs. Controls (n = 25); d.f. 1); ‘Vision’ (eyes closed vs. eyes open; d.f. 1), and when applicable ‘Period’ (vibration 
periods 1, 2, 3, 4; d.f. 3).
The Mann-Whitney U (Exact sig. 2-tailed) test was used for between-groups post hoc comparisons. The 
Wilcoxon matched-pairs signed-rank test (Exact sig. 2-tailed) was used for within-subjects post hoc comparisons, 
i.e., analysing the adaptive changes over time between Period 1 and Period 44,24.
In all analyses, p-values < 0.05 were considered statistically significant, whereas trends were defined as 
(p < 0.1). Non-parametric statistical tests were used in all statistical evaluations since the Shapiro-Wilk test 
revealed that some of the obtained data sets were not normally distributed.
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